CureLab Veterinary develops ElenaVet®, a plasmid-based gene therapy that enhances the immune response against cancer while reducing chronic inflammation in dogs and cats. This therapy targets diseases such as breast cancer and melanoma, demonstrating significant efficacy in clinical studies by improving survival rates and delaying metastasis.
Funding
Funding not disclosed
Founders
Product
Problem
Dogs and cats are increasingly suffering from cancers and chronic inflammatory diseases, mirroring trends in human health. Current anti-inflammatory treatments for pets often target specific cytokines or have high toxicity, while cancer treatments can be expensive and have limited efficacy.
Solution
CureLab Veterinary develops ElenaVet®, a plasmid-based gene therapy that enhances the body's anticancer immune response and reduces chronic inflammation in companion animals. ElenaVet utilizes a plasmid containing a gene-encoding protein p62/SQSTM1. Once injected, the plasmid enters cells and prompts them to produce the p62 protein, which corrects the tumor microenvironment, making it more favorable for anti-cancer immunity, and changes the tumor structure itself, hindering metastasis. By restoring balance in the cells secreting pro- and anti-inflammatory cytokines, ElenaVet comprehensively reduces overall inflammation, addressing conditions such as osteoarthritis, inflammatory bowel disease, and chronic dermatologic issues.
Target Audience
The primary target audience includes veterinarians and pet owners seeking advanced treatment options for cancer and chronic inflammatory diseases in dogs and cats.
Features
- Plasmid-based gene therapy that enhances the anticancer immune response.
- Reduces chronic inflammation by restoring balance in cytokine secretion.
- Alters the tumor microenvironment to support anti-cancer immunity.
- Modifies tumor structure to impede metastasis.
- Contains a gene-encoding protein p62/SQSTM1.
- Manufacturing is outsourced to a contract manufacturing partner experienced with USDA and FDA regulations.
- Administered via simple intramuscular injections.